pluri CELL-BASED TECHNOLOGY PLATFORMS

INVESTOR PRESENTATION

WHERE TECHNOLOGY COMES TO LIFE

FORWARD LOOKING STATEMENT

This presentation contains forward-looking statements within the Israeli Securities Law, 1968, the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws, as amended, regarding Pluri Inc. and/or its subsidiaries (collectively the “Company” or “Pluri”), to the extent such statements do not relate to historical or current facts. For example, the Company is using forward looking statements when it discusses its commercialization, development, and manufacturing activities, the potential of its technology to improve quality of life and make the world a better place, the potential applications of Pluri’s and Ever After Foods’ products, the statement that any industry that requires mass cell production can benefit from Pluri’s technology, its ability to seek and collaborate with strategic partners, its ability to solve medicine’s most urgent unmet needs, the belief that the study results demonstrate PLX-PAD’s ability to trigger muscle regeneration and maintain it over time, that the increase in muscle strength demonstrated in the PLX-PAD study is meaningful clinical evidence that PLX-PAD can be potentially beneficial for a variety of injuries, and the potential of Pluri’s cell expansion technology platform to create new solutions and add value to many verticals and industries. Forward-looking statements are based on management’s current expectations, estimates, projections, and assumptions about future events, and are subject to several factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions about the Company, which are difficult to predict, including projections of the Company’s future financial results, its anticipated growth strategies, and anticipated trends in its business and in the market generally. Therefore, actual future results, performance and trends may differ materially from these forward-looking statements due to a variety of factors, including, without limitation: changes in technology and market requirements; the Company may encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; its products may not be approved by regulatory agencies, their technology may not be validated as they progress further and their methods may not be accepted by the scientific community; it may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with its processes; its products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; its patents may not be sufficient; its products may harm recipients or consumers; changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of the Company or the collaboration to differ materially from those contemplated in such forward-looking statements. The factors listed above are not exclusive, and further information is contained in the Company’s Annual Report on Form 10-K and other reports on file with the U.S. Securities and Exchange Commission. All forward-looking statements speak only as of the date of this presentation. Although the Company believes the expectations reflected in the forward-looking statements contained herein are reasonable, it cannot guarantee future results, level of activity, performance, or achievements. Moreover, neither the Company nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities of the Company. The information to be presented is not intended to replace the need to review the Company’s formal filings with the U.S Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K and any subsequent filings, prior to making any investment in the Company’s securities. In case of any inconsistencies between the information provided in this presentation and the Company’s regulatory filings, the latter will prevail. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

PLURI AT A GLANCE

FINANCIALS

- Nasdaq (PLUR), TASE (PLUR.TA)
- Cash & deposits: ~$45 million
  (as of March 31, 2023)

COMPANY

- Based in Israel with **global presence** over three continents, including the United States and Europe
- **Rich IP portfolio** with 140 patents granted globally
- **In-house** GMP manufacturing facility

INDUSTRIES

- Leaders in the **regenerative medicine field** with assets from early to late clinical development
- Landmark **food-tech collaboration** launched in Q1 2022 with Tnuva Group
- **Biologics industry collaboration** with a major European company to develop a unique biologic API used in drugs that treat liver and gastroenterological diseases
- Potential **agri-tech industry** applications

OUR GREATEST ASSET

Pluri's proprietary 3D cell expansion technology

Powering robust cell expansion platforms, transforming cells into solutions that promote global wellbeing and sustainability

THE EVOLUTION OF PLURI'S 3D CELL-EXPANSION TECHNOLOGY PLATFORMS

- Nearly **20 years of experience** perfecting a manufacturing process to grow cells efficiently in mass quantities
- **Developing an innovative line** of placenta cell product candidates in regenerative medicine to treat unmet medical needs
- **Targeting early development collaborations** with pharmaceutical partners, to create the next generation of cell-based product candidates

THERAPEUTIC AREA	PRODUCT	INDICATION	LOCATION	FUNDING/ PARTNER	PHASE I	PHASE II	PHASE III
Muscle Injuries	PLX-PAD	Muscle Regeneration following Hip Fracture	U.S., Europe, Israel	European Commission			
Hematology	PLX-PAD	Chronic Graft vs. Host Diseases (cGvHD)	Israel	TEL AVIV SOURASKY MEDICAL CENTER			
	PLX-R18	Acute Radiation Syndrome*	U.S.	NIH NIAID			
	PLX-R18	Hematopoietic Recovery following Hematopoietic Cell Transplantation (HCT)	U.S., Israel				

* Via FDA Animal Rule

TODAY,

WE OFFER ROBUST CELL EXPANSION TECHNOLOGY PLATFORMS THAT CREATE **NEW CELL-BASED SOLUTIONS**.

OUR TECHNOLOGY HAS THE POTENTIAL TO IMPROVE **QUALITY OF LIFE** AND **MAKE OUR WORLD A BETTER PLACE**.

PLURI'S 3D CELL EXPANSION TECHNOLOGY PLATFORMS

The Pluri technology platforms leverage the basic building blocks of life—cells—to create medicine, food and cell-based materials that can **change the course of human history**.

PLURI'S **ADVANTAGES**

- Patented, proprietary **3D cell expansion technology** to produce **high-quality** cells in **mass quantities**
- **Scalable**, automated, efficient, reliable and **fully controlled** process
- **Cost-effective**, consistent and validated process
- Suitable for **multiple cell sources**: human, animal and plant
- Robust **in-house** GMP (Good Manufacturing Practice) manufacturing facility
- Proven **batch-to-batch consistency**
- Manufacturing process **approved by key regulators**

FDA | EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH | State of Israel Ministry of Health משרד הבריאות | Pmda JAPAN

PLURIMATRIX

PluriMatrix is a breakthrough system for unprecedented **industrial scale** production of **cell-based products**

PLURIMATRIX' **ADVANTAGES**

- **Significantly increases industrial scale production** of cell-based products by using a **packed-bed system**
- **Flexible** production to power a range of **cell-based products** for industries such as **pharma, biologics, foodtech, agri-tech and beyond**
- Enables **simultaneous expansion of various cell types** within the same platform, giving each cell type its own growth space
- PluriMatrix' **state-of-the-art modular** cell production system enables a smaller infrastructure, significantly **reducing cost and ecological footprint**

PLURI'S CELL EXPANSION TECHNOLOGY PLATFORMS

The potential applications are almost endless.

Any industry that requires mass cell production can potentially benefit from Pluri's patented technology.

BUSINESS DEVELOPMENT STRATEGY

Drive development and in-house manufacturing of innovative new cell-based products and solutions powered by Pluri’s 3D cell expansion technology platforms

Joint ventures and partnerships that leverage Pluri’s cell expansion technology and cell-based product portfolio to expand product pipelines and meet cell-based manufacturing needs for a variety of industries

PLURI TODAY

plurihealth

plurifood

plurifood

RETHINKING HOW TO FEED OUR PLANET

Cell expansion technology is the cornerstone to producing high quality, mass scale, cost-effective, cultivated food products in a **more efficient** and **sustainable manner**.

As cultivated food is one of the fastest growing industries in the world today, we believe there is a **significant market opportunity** for Pluri to become a global leader in cell expansion technology for the food industry.

PLURIFOOD INITIATIVES:

Cultivated meat (Ever After Foods)

Cultivated meat is estimated to become a $140 billion market by 2030[1]

Cultivated fish and seafood

Cultivated fish is estimated to become a $8.7 billion market by 2031[2]

Cultivated dairy

Cultivated dairy is estimated to become a $6.94 billion market 2032[3]

1 “The future of food”, 4 May 2021, Barclays news
2 https://www.factmr.com/report/fish-meal-market
3 https://www.futuremarketinsights.com/reports/cultured-dairy-blends-market

CELL-BASED IS BETTER

CELL-BASED MEAT AND CULTIVATED FOOD ADVANTAGES

ENVIRONMENTAL

- Uses significantly **less land and water** than conventional farming and breeding
- Emits **fewer greenhouse gases**
- Reduces **agriculture-related pollution**
- Provides solutions to feed the **ever-growing population**

ETHICAL

- Adheres to ethical **animal welfare** standards

CONSUMER

- Facilitates **natural flavor modification**
- Enables safe modification for **healthier, more nutritious foods** and raw materials

PLURI'S CELL EXPANSION TECHNOLOGY PLATFORM FOR FOOD-TECH

Uniquely poised to power the full production chain for the development and manufacturing of affordable, high-quality cultivated products for the food industry.

- Development of suitable and efficient animal origin-free cell culture media
- Scalable bioprocessing design
- Robust process to drive down costs and enable large-scale production
- Suitable for animal and plant cells



PLURI'S **3D CELL EXPANSION** PLATFORM

Grows cells quickly and reliably, with unique batch-to-batch consistency in a highly cost-effective process that can be applied to human, animal, and plant cells

LANDMARK COLLABORATION FOR CULTIVATED FOOD PLATFORM

EVER AFTER FOODS

Joint venture to develop, manufacture and commercialize cell-based meat products for the food industry, announced in early 2022.

Bringing sustainable, affordable cultivated food to consumers across the globe.

COLLABORATION OF TWO PROVEN PIONEERS

Pluri and Tnuva Group may expand the collaboration to include cultivated dairy and fish products by establishing separate, new ventures.

"…We chose to collaborate with Pluri (formerly Pluristem) because we believe it owns one of the most advanced cell production technologies in the world. We expect the collaboration between the companies to revolutionize the cultivated food industry and develop the next generation of alternative proteins."
Eyal Malis, CEO Tnuva Group

EVER AFTER FOODS JOINT VENTURE TERMS

- Tnuva invested $7.5 million in the Ever After Foods JV based on a **$40 M pre-money valuation.**
- Pluri granted to Ever After Foods an exclusive global royalty-bearing **license to use its IP and expertise** in the field of cultivated meat.
- **Tnuva** receives exclusive rights to **market Ever After Foods' products in Israel**.
- Ever After Foods retains rights to **out-license marketing** of its cultivated meat products in the rest-of-world **outside of Israel.**

Pluri's mass-scale, cost-effective, consistent cell production expertise and technology platform

Tnuva Group's power multipliers in consumer-packaged goods, R&D, consumer branding, marketing, sales and distribution

pluri **~84.2%**

- Mass-scale, cost-effective, consistent 3D cell expansion platform
- Proven cell expansion technology
- Potential to produce cultivated meat cells at mass scale
- Supports expansion of a wide variety of cells
- Robust IP portfolio
- Regulatory expertise in cells

TNUVA **~15.8%**

- Israel's largest food producer, with +95 years of experience
- Proven pioneer in the field of alternative protein
- Strong consumer goods R&D platform
- Regulatory expertise
- Global sales, marketing and distribution infrastructure

pluri health

TRANSFORMING THE MIRACLE OF BIRTH INTO BETTER HEALTH FOR ALL

Medicine and healthcare can be transformed by the smallest existing organism

Since 2003, Pluri has perfected methods to expand a single placenta cell into billions of distinct cells.
The 3D cell expansion technology drives the development of groundbreaking cell-based therapies that solve some of medicine's most urgent unmet needs.

Pluri's technology platform accelerates the development and approval of more targeted, personalized and well-tolerated allogeneic treatments, with no need for genetic matching.

CHANGING THE FACE OF MEDICINE, ONE CELL AT A TIME

CELL-BASED IS BETTER

Cell therapy will take us from chronic treatments and hospitalizations to smart therapies that will heal and regenerate our bodies

ADVANTAGES OF CELL THERAPIES

SCIENTIFIC

- Cell therapies encourage the body to regenerate and heal itself, addressing **unmet medical needs**
- **No need for genetic matching**. Cell-based therapies allow immune systems to coexist side by side without immune rejection, allowing the body to heal itself

REACH

- Cells from a single placenta can help **20,000+ patients**
- **Ethically sourced**, endless and consistent supply of **young, potent cells**

FUTURE

- **Manufacturing flexibility** is key to ushering in new cell-based products and solutions
- Innovative treatments for an **ever-growing and aging population**

“The placenta is one of the least understood human organs but probably one of the most important.”

The U.S. National Institute of Health

PLURI'S PLATFORMS IN HEALTHCARE AND MEDICINE

Uniquely poised to power the full production chain for the development and manufacture of affordable, high-quality cell-based products for the pharma and healthcare sectors.

ADVANTAGES OF PLURI'S CELL TECHNOLOGY PLATFORMS

- Optimizing cell lines
- Generic off-the-shelf usability, requires no tissue matching
- Development of suitable and efficient cell culture media
- Scalable bioprocessing design
- Driving down costs with a robust, scalable process



PLURI'S **3D CELL EXPANSION** PLATFORM

Grows cells quickly and reliably, with unique batch-to-batch consistency in a highly cost-effective process

SIGNIFICANT SUPPORT FROM LEADING ORGANIZATIONS

REGULATORY

FDA

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

State of Israel
Ministry of Health
משרד הבריאות

pmda JAPAN

MFDS KOREA

SCIENTIFIC COLLABORATIONS AND PARTNERING

CHARITÉ
UNIVERSITÄTSMEDIZIN BERLIN

NIH National Institute of Allergy and Infectious Diseases

TNUVA

NASA

CRISPRIL

TEL AVIV SOURASKY MEDICAL CENTER

CHA BiOtech

ADSCC
مركز أبو ظبي للخلايا الجذعية
ABU DHABI STEM CELLS CENTER

hipgen

FUKUSHIMA MEDICAL UNIVERSITY

FUNDING

European Commission

European Investment Bank
The EU bank

NIH National Institute of Allergy and Infectious Diseases

רשות החדשנות
Israel Innovation Authority

ADVANCED AND ONGOING CLINICAL STUDIES

Phase I/II study of PLX-PAD for muscle injury following total hip replacement (N=20)

- PLX-PAD demonstrated a significant increase in muscle strength & volume compared to placebo
- There are currently no approved treatments for the post-operative regeneration of injured or weak skeletal muscle



Change in Volume P=0.004



Change in Strength P=0.0067



Change in Strength P=0.0012



ADVANCED AND ONGOING CLINICAL STUDIES

Phase III study of PLX-PAD for muscle injury following hip fracture surgery (N=240), results reported in July 2022

- The study did not meet the primary endpoint, which was the Short Physical Performance Battery (SPPB) test at week 26
- A significant increase in Hip Abduction Strength (HAS) was observed at week 26 and week 52, compared to reference week 6, for patients treated with PLX-PAD (n=120), in the injured and uninjured leg compared to placebo (n=120)
- PLX-PAD demonstrated a meaningful increase in the absolute HAS at week 52 in the injured leg (p=0.0511) and uninjured (p=0.113) leg
- PLX-PAD treated patients were able to walk 296 meters versus 266 meters in placebo during 6-min walking test at week 52
- € 7.4 million grant from the EU Horizon 2020 program

hipgen | European Commission

HAS change from week 6 Injured leg

2KG difference from placebo at W26 (p=0.047)

4KG difference from placebo at W52 (p=0.0022)



HAS change from week 6 Contralateral (non–operated leg)

1.8KG difference from placebo at W26 (p=0.073)

4KG difference from placebo at W52 (p=0.0046)



ADVANCED AND ONGOING CLINICAL STUDIES

PLX-R18 for Acute Radiation Syndrome (ARS)

ARS, also known as radiation sickness or radiation poisoning, is caused by exposure to high amounts of ionizing radiation, such as in nuclear reactor accidents or warfare

- Studies conducted and funded by U.S. government
- FDA cleared Investigational New Drug (IND) application for PLX-R18 for the treatment of ARS in case of nuclear events
- FDA Orphan Drug Designation

Significant increase in survival rate (68%) versus placebo (p<0.0001)

Significant increase in survival rate (68%) versus placebo (p<0.0001)



Significant recovery of the three blood lineages (p<0.001)

Plt



RBC



WBC





National Institute of Allergy and Infectious Diseases
National Institutes of Health

המרכז הרפואי האוניברסיטאי הדסה
מיסודו של ארגון נשות הדסה

FUKUSHIMA MEDICAL UNIVERSITY

ADVANCED AND ONGOING CLINICAL STUDIES

PLX-R18 to stimulate the regeneration of damaged bone marrow following Hematopoietic Cell Transplantation (HCT)

Positive Phase I results to demonstrate the safety and exploratory efficacy of PLX-R18 in humans reported March 2022

- PLX-R18 reduced mortality from 29% to 18% and was well-tolerated with a favorable safety profile*
- Decreased mean number of transfused units from a monthly 5.09 to 0.55 for platelets (p=0.045) and 2.91 to 0 for red blood cells (p=0.0005) at 12 months
- Increase in all three blood cell types with platelets (p<0.001), hemoglobin (p=0.02) and neutrophils (p=0.15) levels increasing, enduring up to 12 months

At 6 months:
p = 0.0020

At 12 months:
p = 0.0187



At 6 months:
p = 0.0628

At 12 months:
p = 0.1468



At 6 month:
p = 0.0004

At 12 month:
p < 0.0001



* When compared to data obtained from the CIBMTR registry during a 12-month interval from first observation. First observation was defined as the day of first PLX-R18 treatment for the Phase I patients and as day 100 post-HCT for the CIBMTR population.

PLURI IS PART OF THE PROTO CONSORTIUM

Phase I/IIa study of PLX-PAD for the treatment of mild to moderate knee osteoarthritis (OA)

- OA is one of the most common chronic articular diseases, global prevalence of 16% in the adult population1. Third most rapidly growing disease associated with disability2, affecting over 500 million people worldwide3
- Other than joint replacement surgery, there is currently no effective disease-modifying therapy for OA
- Pluri is part of PROTO (Advanced PeRsOnalized Therapies for Osteoarthritis), an international collaboration led by Charité Berlin
- PROTO received a €7.5 million grant from the EU Horizon Europe program

Chronic inflammation in the articular environment causes cartilage degeneration at an early stage, resulting in pain, disability and loss of independence due to progressive joint destruction.

OA manifests as joint inflammation, pain, stiffness, swelling, disability and is associated with reduced quality of life and work performance

*Final approval of the grant is subject to the finalization of the consortium and Horizon 2020 grant agreements

PROTO Personalized Therapies for Osteoarthritis | European Commission | CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN

1 Cui et al., 2020, PMID: 34505846
2 Hawker et al., 2019, PMID: 31621562
3 Hunter et al., 2020, PMID:33159851

NEXT-GENERATION PRODUCTS

INDUCED PLX CELLS

- PLX-R18 is the first product candidate to successfully use technology to induce PLX cells with different cytokines to alter their secretion profile
- Positive data from hematology (HCT) study using PLX-R18 supports indication-specific enhancement of cell activity
- Pipeline of additional targeted products in development using genetic engineering approaches

GENETICALLY MODIFIED CELLS

- Collaboration with CRISPR-IL consortium developing genetically edited PLX cells tailored for treatment of indications with unmet needs

רשות החדשנות
Israel Innovation Authority

CRISPRIL

OUR MISSION

To leverage our advanced cell expansion platforms and position as a global leader in cell technology to develop, manufacture and market highly effective cell-based products and solutions that enhance global wellbeing and promote sustainability

Pluri Today **Pluri Tomorrow**



COMMITMENT TO EXCELLENCE

Yaky Yanay
CEO & President

Chen Franco-Yehuda
Chief Financial Officer

Dr. Nitsan Halevy, MD
Chief Medical Officer

Lior Raviv
Chief Technology Officer

Nimrod Bar Zvi
Chief Commercial Officer

Dr. Arthur Machlenkin, PhD
Chief Scientific Officer

Efrat Livne-Hadass
Chief Wellbeing Officer

Orly Amiran
Chief Quality Officer

Efrat Kaduri
Chief Business Development Officer - Pharma

COMMITMENT TO MAKING A POSITIVE IMPACT

In the workplace

- Ranked in Dun's 100 top **50 Best High-Tech Companies to work for** from 2016-2021
- **Gender equality** throughout company, including executive management
  - Awarded the 2022 Egalitarian Employment Award from the Israeli Ministry of Labor, Social Affairs and Social Services, for the second time in a row, for the promotion of women in the workplace, pay equity and encouragement of a healthy work-family balance

In our society

- Employees contribute 800+ hours per year on **volunteer initiatives** in education and community projects
- **Ethnically and culturally diverse** workforce promoting tolerance and peace
- **Collaboration** with **medical community** and physician training
- Nurturing young talent and curiosity by hosting students in laboratories and **operating educational projects**

On our planet

- Executing **sustainable models** in food-tech to sustain the health of our planet
- Supporting the **recycling of materials** in line with our Environmental and Social Governance strategy
- Developing **new regenerative models** that advance healing to promote a better quality of life



Employees



Entire management level



Senior management

*

*As of August 2022

WHERE TECHNOLOGY COMES TO LIFE

THE PROMISE & THE OPPORTUNITY

Pluri's cell-expansion technology will touch and improve every aspect of our lives.

Promoting sustainability, wellbeing and improving quality of life.

For every one of us. Individually.

And for all of us, as a society. Together.